These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 27696727)

  • 1. Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.
    van der Heijde D; Deodhar A; Fleischmann R; Mease PJ; Rudwaleit M; Nurminen T; Davies O
    Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1030-1039. PubMed ID: 27696727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?
    Iannone F; Semeraro A; Carlino G; Santo L; Bucci R; Quarta L; Maruotti N; Zuccaro C; Marsico A; Falappone PCF; Mazzotta D; Cantatore FP; Muratore M; Lapadula G
    Clin Drug Investig; 2019 Jun; 39(6):565-575. PubMed ID: 30941736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
    Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
    Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
    Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
    Gehin JE; Goll GL; Warren DJ; Syversen SW; Sexton J; Strand EK; Kvien TK; Bolstad N; Lie E
    Arthritis Res Ther; 2019 Nov; 21(1):256. PubMed ID: 31783773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psoriatic arthritis and spondyloarthritis assessment and management update.
    Mease P
    Curr Opin Rheumatol; 2013 May; 25(3):287-96. PubMed ID: 23492739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
    Osterhaus JT; Purcaru O
    Arthritis Res Ther; 2014 Aug; 16(4):R164. PubMed ID: 25099160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
    Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
    Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis.
    Rudwaleit M; Marzo-Ortega H; Navarro-Compán V; Tham R; Kumke T; Bauer L; de Peyrecave N; Kim M; Van den Bosch F
    RMD Open; 2024 Aug; 10(3):. PubMed ID: 39209369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
    Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
    Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
    Rudwaleit M; Rosenbaum JT; Landewé R; Marzo-Ortega H; Sieper J; van der Heijde D; Davies O; Bartz H; Hoepken B; Nurminen T; Deodhar A
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):838-44. PubMed ID: 26815944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.
    Dhillon S
    Drugs; 2014 Jun; 74(9):999-1016. PubMed ID: 24919863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.
    Paramarta JE; De Rycke L; Ambarus CA; Tak PP; Baeten D
    Rheumatology (Oxford); 2013 Oct; 52(10):1873-8. PubMed ID: 23861532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.
    Deeks ED
    BioDrugs; 2016 Dec; 30(6):607-617. PubMed ID: 27704400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
    Kilic E; Kilic G; Akgul O; Ozgocmen S
    Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
    Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
    Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
    Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
    Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.